LANTHEUS HOLDINGS INC

LNTH is the ticker symbol for Lantheus Holdings, Inc., a healthcare company whose shares trade on the Nasdaq Global Select Market. The stock represents ownership in a business focused on diagnostic imaging agents and radiopharmaceuticals used in cardiovascular and oncology care. Because LNTH is a single company's equity, its value reflects that business's operations, results, and industry conditions rather than the broader market alone.

Volatility for LNTH can be influenced by company-specific news, clinical and regulatory developments, product demand, and broader market conditions. Because radiopharmaceutical and diagnostic imaging businesses can see sharp reactions to trial data or guidance changes, daily price swings may be wider than those of more diversified healthcare companies. For the latest observed volatility, turnover, and price range data, check the current LNTH quote and statistics shown on this page.

Valuation review for LNTH typically involves comparing its market price with fundamentals such as earnings, sales, cash flow, and book value, along with growth expectations for its product portfolio. Common metrics include the price-to-earnings ratio, price-to-sales ratio, and enterprise value multiples, all of which should be weighed against peers and the company's own history. Use the current LNTH data on this page for up-to-date multiples.

Trading activity for LNTH depends on daily market participation, which can vary with news, earnings, and overall market conditions. A Nasdaq-listed stock generally has continuous quotes during regular sessions, but liquidity may differ across the trading day. To assess actual activity, review the latest LNTH volume, average volume, and bid-ask data displayed on this page rather than relying on a fixed characterization.

For LNTH, key metrics include revenue growth, gross and operating margins, net income, earnings per share, and operating cash flow, since these show how well the company converts imaging-agent sales into profit and cash. Also worth reviewing are research and development spending, product concentration, and balance-sheet items such as debt and cash. These figures are reported in Lantheus's quarterly and annual filings, which provide the underlying data for analysis.

Risks for LNTH include dependence on a limited number of key products, regulatory and reimbursement changes, clinical trial or approval setbacks, and competition in radiopharmaceuticals and diagnostic imaging. Manufacturing and supply constraints for radioactive materials can also matter, as can broader market, interest rate, and economic conditions. These factors can affect revenue and results, so investors often monitor company filings and news for updates.